

## Product datasheet for **TL304729**

### **EVC2 Human shRNA Plasmid Kit (Locus ID 132884)**

#### **Product data:**

<b>Product Type:</b>	shRNA Plasmids
<b>Product Name:</b>	EVC2 Human shRNA Plasmid Kit (Locus ID 132884)
<b>Locus ID:</b>	132884
<b>Synonyms:</b>	LBN; WAD
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>E. coli Selection:</b>	Chloramphenicol (34 ug/ml)
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Lentiviral plasmids
<b>Components:</b>	EVC2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 132884). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
<b>RefSeq:</b>	<a href="#">NM_001166136</a> , <a href="#">NM_147127</a> , <a href="#">NM_147127.1</a> , <a href="#">NM_147127.2</a> , <a href="#">NM_147127.3</a> , <a href="#">NM_147127.4</a> , <a href="#">NM_001166136.1</a> , <a href="#">BC111455</a> , <a href="#">BC143836</a> , <a href="#">NM_147127.5</a>
<b>UniProt ID:</b>	<a href="#">Q86UK5</a>
<b>Summary:</b>	This gene encodes a protein that functions in bone formation and skeletal development. Mutations in this gene, as well as in a neighboring gene that lies in a head-to-head configuration, cause Ellis-van Creveld syndrome, an autosomal recessive skeletal dysplasia that is also known as chondroectodermal dysplasia. Mutations in this gene also cause acrofacial dysostosis Weyers type, also referred to as Curry-Hall syndrome, a disease that combines limb and facial abnormalities. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).